Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta

被引：20
|
作者：
Mehta, Atul [1 ]
Beck, Michael [2 ]
Kampmann, Christoph [2 ]
Frustaci, Andrea [3 ]
Germain, Dominique P. [4 ]
Pastores, Gregory M. [5 ]
Sunder-Plassmann, Gere [6 ]
机构：
[1] UCL Royal Free & Univ Coll Med Sch, Dept Acad Haematol, London NW3 2QG, England
[2] Univ Childrens Hosp, Mainz, Germany
[3] Univ Roma La Sapienza, Heart & Great Vessels Attilio Reale Dept, Rome, Italy
[4] Univ Versailles St Quentin Yvelines, Hop Raymond Poincare, AP HP, UF Genet Med, Garches, France
[5] NYU, Sch Med, Dept Neurol & Pediat, New York, NY USA
[6] Dept Internal Med 3, Div Nephrol & Dialysis, Vienna, Austria
来源：
MOLECULAR GENETICS AND METABOLISM | 2008年 / 95卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2008.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [21] Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa
    Wendt, S
    Whybra, C
    Kampmann, C
    Teichmann, E
    Beck, M
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (05) : 787 - 788
  • [22] An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy
    Richards, Sarah
    Laney, Dawn
    Pervaiz, Muhammad A.
    Shankar, Suma
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S90 - S90
  • [23] Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy
    Hajioff, D
    Enever, Y
    Quiney, R
    Zuckerman, J
    Macdermot, K
    Mehta, A
    JOURNAL OF INHERITED METABOLIC DISEASE, 2003, 26 (08) : 787 - 794
  • [24] MAJOR STROKE IN FABRY PATIENTS UNDER ENZYME REPLACEMENT THERAPY WITH AGALSIDASE ALFA
    Roland, D.
    Dehout, F.
    Van Maldergem, L.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 167 - 167
  • [25] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
    Hollak, Carla E.
    Arends, Maarten
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry
    Oder, Daniel
    Watkinson, Oliver
    Bichet, Daniel
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic
    van Kuilenburg, Andre B.
    West, Michael L.
    Hughes, Derralynn A.
    Biegstraaten, Marieke
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S64 - S65
  • [26] Enzyme replacement in Fabry disease: Pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents
    Ries, Markus
    Clarke, Joe T.
    Whybra, Catharina
    Mehta, Atul
    Loveday, Kenneth S.
    Brady, Roscoe O.
    Beck, Michael
    Schiffmann, Raphael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (10): : 1222 - 1230
  • [27] Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
    Mehta, A.
    Beck, M.
    Elliott, P.
    Giugliani, R.
    Linhart, A.
    Sunder-Plassmann, G.
    Schiffmann, R.
    Barbey, F.
    Ries, M.
    Clarke, J. T. R.
    LANCET, 2009, 374 (9706): : 1986 - 1996
  • [28] Antibody measurement on switching from agalsidase alfa to agalsidase beta in the treatment of Fabry disease
    Peters, C.
    Burling, K.
    Deegan, P. B.
    ACTA PAEDIATRICA, 2008, 97 : 111 - 112
  • [29] Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani, Antonio
    Riccio, Eleonora
    Sabbatini, Massimo
    GENETICS IN MEDICINE, 2015, 17 (01) : 21 - 23
  • [30] SAFETY AND TOLERABILITY OF AGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE FORMERLY TREATED WITH AGALSIDASE BETA
    Fernhoff, P.
    Goker-Alpan, O.
    Holida, M.
    Nedd, K.
    Barshop, B. A.
    Mardach, R.
    Ibrahim, J.
    Lien, Y. H.
    Rever, B.
    Hillman, R.
    Weinreb, N.
    Boyd, E.
    Desai, A.
    Forte, R.
    Crombez, E.
    Martin, R.
    Amato, D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S227 - S227
12345